H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

NCT05872841 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Primary Hepatocellular Carcinoma
Portal Vein Thrombosis

Interventions

DRUG: Recombinant human adenovirus type 5 + TACE

Sponsor

Tianjin Medical University Cancer Institute and Hospital